Trellis Bioscience secures Series C financing for TRL1068 trial
Trellis Bioscience has closed a $9m Series C funding round to support the completion of its ongoing Phase II clinical…
All articles by Salong Debbarma
Salong Debbarma
-
-
First patients dosed in Grifols Phase III immunoglobulin trials
Grifols has dosed the first patients in two separate Phase III trials designed to support the US label expansion of…
-
MediciNova achieves target enrolment in SEANOBI-ALS study of MN-166
MediciNova has achieved the target enrolment of 200 patients in the SEANOBI-ALS clinical study, evaluating MN-166 (ibudilast) for amyotrophic lateral…
-
Kairos Pharma announces interim Phase I data for ENV-105 in NSCLC
Kairos Pharma has reported interim safety results from its ongoing Phase I clinical trial of ENV-105 (carotuximab), along with AstraZeneca's…
-
FDA clears Atrium’s IND application to begin Corventis trial of ATR 1072
Atrium Therapeutics has received clearance from the US Food and Drug Administration (FDA) for its investigational new drug (IND) application…
-
Sound Pharmaceuticals concludes subject enrolment for SPI-1005 trial
Sound Pharmaceuticals has concluded subject enrolment for its second Phase III clinical trial assessing SPI-1005 in adults with probable or…
-
Q32 Bio reports 36-week data from SIGNAL-AA trial’s Part B in alopecia areata
Q32 Bio has reported positive 36-week top line data from Part B of the SIGNAL-AA Phase IIa trial of bempikibart…
-
First participant dosed in Ionis’ Phase I-II ASCEND study
Ionis Pharmaceuticals has dosed the first participant in its Phase I-II ASCEND trial evaluating ION337, an investigational ribonucleic acid (RNA)-targeted…
-
Serina concludes sentinel dosing in Phase Ib trial’s Cohort 1
Serina Therapeutics has completed sentinel dosing in Cohort 1 of its ongoing Phase Ib registrational trial assessing SER-252 in adults…
-
Novo Nordisk reports Phase III FRONTIER4 study results for denecimig
Novo Nordisk has reported positive results from the ongoing Phase III FRONTIER4 extension trial, assessing the long-term safety and efficacy…